# OnCo record ror1 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/ror1/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "ror1" ;
  schema:name "ROR1"@en ;
  schema:description "ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven."@en ;
  schema:url <https://onco.cc/targets/ror1/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/ROR1>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10256>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185483>, <https://www.uniprot.org/uniprotkb/Q01973/entry>, <https://www.ncbi.nlm.nih.gov/gene/4919> ;
  owl:sameAs <http://www.wikidata.org/entity/Q18030230> ;
  schema:citation <https://en.wikipedia.org/wiki/ROR1> ;
  onco:tag "adc-target" ;
  schema:alternateName "ROR1" ;
  onco:targetClass "surface-antigen" ;
  onco:firstDescribed "1992"^^xsd:gYear ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/zilovertamab-vedotin/> ;
  onco:trials <https://onco.cc/trials/nct07510802/> .